Clinical trial · Interventional
Effects of Abdominal Nerve Block on Postoperative Recovery in Patients Undergoing Gastrointestinal Surgery
NCT04147481CI-TRIAL-00041605unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the effect of general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) on the recovery of patients with gastrointestinal tumor after surgical treatment.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Group Abdominal Nerve Block with local anesthetics | Other | — | UNRESOLVED |
| Group Abdominal Nerve Block with saline | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group Abdominal Nerve Block
- description
- surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
- interventionNames
- Other: Group Abdominal Nerve Block with local anesthetics
- type
- PLACEBO_COMPARATOR
- label
- Group control
- description
- surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.9% saline.
- interventionNames
- Other: Group Abdominal Nerve Block with saline
Primary outcomes (1)
- measure
- Incidence of postoperative chronic pain
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18 to 80 years. 2. ASA 1-3. 3. Clinical diagnosis of gastric carcinoma and colorectal cancer without metastasis. 4. Surgery for gastrointestinal surgery. Exclusion Criteria: 1. Patients and their family members refuse to accept the clinical trial; 2. Complicated with acute cholangitis, gastrointestinal bleeding or ascites, etc.; 3. Hepatic encephalopathy, psychosis or neuropathy; 4. Body weight for acid-base and electrolyte imbalances, endotoxemia, and cachexia decreased by more than 2% or 5% in the past 2 months or 6 months. 5. Uncontrolled hypertentsion, coronary heart disease, diabetes.
References
Publications (0)
Data not yet available
No reference posted for this study.